Nontargeted metabolomics uncovering metabolite signatures in glioblastoma: a preliminary study on candidate biomarker discovery for IDH subtyping and survival prediction
BackgroundCurrently, there are no established tumor-derived metabolic biomarkers in clinical practice that can simultaneously differentiate among nontumorous brain tissues, isocitrate dehydrogenase (IDH) wild-type glioblastomas (GBMs), and IDH mutant GBMs, or accurately predict patient survival. The...
Збережено в:
| Автори: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2025-05-01
|
| Серія: | Frontiers in Oncology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1568040/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|